Home » Stocks » COCP

Cocrystal Pharma, Inc. (COCP)

Stock Price: $2.21 USD -0.14 (-5.96%)
Updated Jan 21, 2021 11:36 AM EST - Market open
Market Cap 150.15M
Revenue (ttm) 1.91M
Net Income (ttm) -56.00M
Shares Out 57.56M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $2.21
Previous Close $2.35
Change ($) -0.14
Change (%) -5.96%
Day's Open 2.26
Day's Range 2.03 - 2.30
Day's Volume 3,414,515
52-Week Range 0.50 - 2.36

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 1 day ago

Cocrystal Pharma (NASDAQ: COCP) shares are trading higher after the company announced it has completed all research obligations under the Merck exclusive worldwide license and collaboration ag...

Other stocks mentioned: DTIL
GlobeNewsWire - 2 days ago

Program advances within the agreement's initial two-year timeframe

GlobeNewsWire - 1 week ago

BOTHELL, Wash., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...

GlobeNewsWire - 1 week ago

BOTHELL, Wash., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...

GlobeNewsWire - 4 weeks ago

CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2

Pulse2 - 1 month ago

The stock price of Cocrystal Pharma, Inc. (NASDAQ: COCP) increased by 111.17% over the past week as it went from $0.90 per share on November 20 to $1.89 per share as of today. This is why it h...

InvestorPlace - 1 month ago

Cocrystal Pharma (COCP) is on the move Wednesday even with there being a lack of news concerning the pharmaceutical company. The post Cocrystal Pharma: 8 Things for COCP Investors to Know Abou...

GlobeNewsWire - 2 months ago

– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by ...

GlobeNewsWire - 2 months ago

BOTHELL, WA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel an...

GlobeNewsWire - 2 months ago

– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST –

GlobeNewsWire - 3 months ago

– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain –

GlobeNewsWire - 3 months ago

BOTHELL, WA, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP) The following is being released by Cocrystal Pharma, Inc. pursuant to an order of the United States Distric...

GlobeNewsWire - 4 months ago

– Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14th at 3:30 PM EDT –

GlobeNewsWire - 4 months ago

BOTHELL, WA, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing nove...

GlobeNewsWire - 4 months ago

BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing nove...

GlobeNewsWire - 4 months ago

BOTHELL, WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing nove...

GlobeNewsWire - 5 months ago

– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing –

GlobeNewsWire - 5 months ago

– Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication –

Forbes - 6 months ago

Markets are down today, pretty much from the get-go. As investors become increasingly concerned with the worsening coronavirus cases, it's become clear that a sell-off is imminent.

Other stocks mentioned: AMRS, BKYI, MRAM, OSBC
Forbes - 6 months ago

Despite valuations looking expensive, the markets are in a good place as of this morning, despite the cases for coronavirus spiking over the weekend. Some may say the market is getting ahead o...

Other stocks mentioned: BKYI, EYES, EYPT, REPH
Forbes - 7 months ago

With the S&P 500, Nasdaq, and Dow going positive today, we link the markets are overextended. Our deep learning and AI has identified several Top Shorts today for you to hedge your portfolio w...

Other stocks mentioned: BLNK, ECOR, TTPH
Forbes - 7 months ago

We have some buying this morning with markets recovering some of Thursday’s massive losses. However, it looks uneasy at best.

Other stocks mentioned: ECOR, INSE, KMPH
Forbes - 7 months ago

This week has been a successful one for markets, with the S&P 500 entering positive territory on the year. If you’re looking to hedge the rally, our deep learning algorithms have identified se...

Other stocks mentioned: BLNK, DMTK, TTPH
GlobeNewsWire - 8 months ago

- Company has sufficient capital to advance pipeline and fund operations through 2021 -

GlobeNewsWire - 8 months ago

– Company reprioritizes activities to accelerate development and provides next steps for advancing preclinical COVID-19 Coronavirus program –

GlobeNewsWire - 8 months ago

- Expanded license agreement with KSURF further broadens and advances Cocrystal’s COVID-19 program -

GlobeNewsWire - 9 months ago

- Work completed over decades of renowned biochemist’s career serves as basis for Company’s structure-based technology which has demonstrated broad utility in development of proprietary antivi...

GlobeNewsWire - 9 months ago

– Presentation with live audio webcast on Wednesday, April 22 at 11:00 AM ET, immediately followed by an interactive Q&A session –

GlobeNewsWire - 9 months ago

BOTHELL, WA, March 30, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing no...

GlobeNewsWire - 10 months ago

BOTHELL, WA, March 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel ...

Benzinga - 10 months ago

The COVID-19 virus has sent the market and the global economy into a tailspin. The Organisation for Economic Co-operation and Development slashed its global growth forecast for 2020 Monday by ...

Other stocks mentioned: GILD, GSK, INO, JNJ, MRNA, NNVC, NVAX, PFE, SNY, VXRT
GlobeNewsWire - 10 months ago

BOTHELL, WA, March 09, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel ...

Benzinga - 10 months ago

The major U.S. stock market averages were all tumbling close to 5% and bond yields were hitting record lows Monday following oil's plunge in the wake of the wrangling between Saudi Arabia and ...

Other stocks mentioned: AIM, SPEX
GlobeNewsWire - 10 months ago

BOTHELL, WA,, March 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing nov...

GlobeNewsWire - 10 months ago

BOTHELL, WA, Feb. 28, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC.  (NASDAQ : COCP ) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developin...

GlobeNewsWire - 10 months ago

BOTHELL, WA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC.  ( NASDAQ: COCP ) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing nov...

Benzinga - 10 months ago

Cocrystal Pharma Inc (NASDAQ: COCP) shares are skyrocketing Monday following a licensing agreement the company reached with the Kansas State University Research Foundation.

GlobeNewsWire - 11 months ago

     –   Positive preclinical and clinical data obtained to date in hepatitis C, influenza and norovirus programs bolster confidence in potential of our platform to address additional viral di...

GlobeNewsWire - 11 months ago

– Presentation on Tuesday, February 18th at 11:30 AM ET –

GlobeNewsWire - 11 months ago

BOTHELL, WA, Feb. 03, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel a...

GlobeNewsWire - 11 months ago

BOTHELL, WA, Jan. 29, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel a...

GlobeNewsWire - 1 year ago

– Presentation on Tuesday, December 10th at 4:40 pm PST –

GlobeNewsWire - 1 year ago

– Following new positive data from Phase 2a study, Company outlines next steps in clinical development plan for lead program CC-31244 for ultrashort treatment of hepatitis C (HepC) –

GlobeNewsWire - 1 year ago

- New data presented at the American Association for the Study of Liver Diseases (AASLD) 2019 Liver Meeting -

GlobeNewsWire - 1 year ago

BOTHELL, WA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel a...

GlobeNewsWire - 1 year ago

BOTHELL, WA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing nov...

GlobeNewsWire - 1 year ago

- Novel class of HCV antivirals targeting the NS3 helicase that can be studied for the treatment of chronic HCV infection developed utilizing Company’s unique structure-based drug design plat...

GlobeNewsWire - 1 year ago

- Presentation on Friday, October 4th at 1:45 PM ET -

GlobeNewsWire - 1 year ago

- CC-42344 showed broad spectrum activity, excellent anti-influenza activity (EC50

GlobeNewsWire - 1 year ago

BOTHELL, WA, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing nove...

About COCP

Cocrystal Pharma, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating infl... [Read more...]

Industry
Biotechnology
CEO
Gary Wilcox
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
COCP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for COCP stock is "Buy." The 12-month stock price forecast is 4.75, which is an increase of 114.93% from the latest price.

Price Target
$4.75
(114.93% upside)
Analyst Consensus: Buy